A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and hemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction

Cristina Tita , Edward M Gilbert , Adrian B Van Bakel , Jacek Grzybowski , Garrie J Haas , Mohammad Jarrah , Stephanie H Dunlap , Stephen S Gottlieb , Marc Klapholz , Parag C Patel , Roman Pfister , Tim Seidler , Keyur B Shah , Tomasz Zieliński , Robert P Venuti , Douglas Cowart , Shi Yin Foo , Alexander Vishnevsky , Veselin Mitrovic

BMS-986231 demonstrated a favorable safety and hemodynamic profile in patients hospitalized with advanced heart failure. Based on preclinical data and these studies’ findings, it is possible that the hemodynamic benefits may be mediated by inotropic and/or lusitropic as well as vasodilatory effects.

For the full article click here

Contact Us

Stay updated with our monthly newsletter

We promise quality content and no spam! :)

Skip to content